Exp Clin Endocrinol Diabetes 2021; 129(04): 303-308
DOI: 10.1055/a-0875-3988
Article

Association between Flash Glucose Monitoring and Metabolic Control as well as Treatment Satisfaction in Outpatients With Diabetes Type 1

Guido Kramer
1   FB Endocrinology and Metabolic Diseases, Department Internal Medicine III, Jena University Hospital, Jena
,
Laura Michalak
1   FB Endocrinology and Metabolic Diseases, Department Internal Medicine III, Jena University Hospital, Jena
,
Ulrich Alfons Müller
1   FB Endocrinology and Metabolic Diseases, Department Internal Medicine III, Jena University Hospital, Jena
,
Christof Kloos
1   FB Endocrinology and Metabolic Diseases, Department Internal Medicine III, Jena University Hospital, Jena
,
Christoph Werner
1   FB Endocrinology and Metabolic Diseases, Department Internal Medicine III, Jena University Hospital, Jena
,
Nadine Kuniss
1   FB Endocrinology and Metabolic Diseases, Department Internal Medicine III, Jena University Hospital, Jena
› Author Affiliations

Abstract

Objective The aim of this study was to follow-up people with diabetes type 1 and Flash Glucose Monitoring (FGM) regarding metabolic control and treatment satisfaction.

Methods 40 people with diabetes type 1 and FGM use of ≥6 months were included in the study (female 55%, age 50.9 y, diabetes duration 21.9 y, HbA1c 7.4%, 57.6 mmol/mol, insulin pump therapy 32.5%). The number of scans per day and time/frequency of hypoglycaemia (interstitial glucose value ≤3.9 mmol/l) was recorded from 28 days of the glucose readings. Change of treatment satisfaction was assessed with the DTSQc questionnaire at follow-up (range−18 to+18).

Results Mean time of follow-up was 1.0±0.4 y. At follow-up, all participants scanned interstitial glucose 11.9±7.7 times/day. Number of self-monitoring of blood glucose decreased from 6.7±4.2 (baseline) to 0.9±1.8 (follow-up) per day (p<0.001). In individuals with baseline HbA1c ≤7.5%, HbA1c increased (from 6.6±0.7% to 7.0±0.4%, p=0.020). On the contrary, in people with HbA1c>7.5%, HbA1c decreased (from 8.2±0.7% to 7.8±0.7%, p=0.001). In all participants, there were no differences regarding insulin dosage (33.8±12.9 vs. 34.6±13.9 IU/day, p=0.679) and number of insulin injections/day (3.9±2.3 vs. 4.0±2.6, p=0.813) between baseline and follow-up. Frequency of symptomatic hypoglycaemia was at baseline 0.3±0.3 events/day and 0.48±0.36 events/day (recognised, symptomatic events) at follow-up, respectively. In addition, 0.26±0.21 unrecognised hypoglycaemic events/day occurred at follow-up. Treatment satisfaction increased by+12.6 points.

Conclusions FGM was associated with an enormous increase in treatment satisfaction and slightly improved metabolic control in people with baseline HbA1c>7.5%. The number of capillary glucose measurements decreased significantly.



Publication History

Received: 18 January 2019
Received: 28 February 2019

Accepted: 13 March 2019

Article published online:
11 June 2019

© 2019. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Bailey T, Bode BW, Christiansen MP. et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther 2015; 17: 787-794
  • 2 Bolinder J, Antuna R, Geelhoed-Duijvestijn P. et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non-masked, randomised controlled trial. Lancet 2016; 388: 2254-2263
  • 3 Haak T, Hanaire H, Ajjan R. et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: A Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther 2017; 8: 55-73
  • 4 Schumann M. Electronic medical information system for long-term documentation of chronic diseases (EMIL). 2015; http://cleverdoku.de (Last accessed 04.01.2016)
  • 5 Seaquist ER, Anderson J, Childs B. et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384-1395
  • 6 Bradley C. (ed.) The diabetes treatment satisfaction questionnaire: DTSQ. Handbook of Psychology and Diabetes: A Guide to Psychological Measurements in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers; 1994
  • 7 Dulon M, Bardehle D, Blettner M. [Assessing social inequality in microcensus data and german national health examination survey]. Gesundheitswesen 2003; 65: 629-635
  • 8 Massa GG, Gys I, Op't Eyndt A. et al. Evaluation of the freestyle® libre flash glucose monitoring system in children and adolescents with type 1 diabetes. Horm Res Paediatr 2018; 89: 189-199
  • 9 Dover AR, Stimson RH, Zammitt NN. et al. Flash Glucose Monitoring Improves Outcomes in a Type 1 Diabetes Clinic. J Diabetes Sci Technol 2017; 11: 442-443
  • 10 Bidonde J, Fagerlund BC, Frønsdal KB. et al. FreeStyle libre flash glucose self-monitoring system: A single-technology assessment [internet]. niph systematic reviews. oslo, norway: Knowledge centre for the health services at the norwegian institute of public health (NIPH); Report from the Norwegian Institute of Public Health No; 2017. Aug 2017 07
  • 11 Leelarathna L, Wilmot EG. Flash forward: A review of flash glucose monitoring. Diabet Med. 2018; 35: 472-482
  • 12 Mitsuishi S, Nishimura R, Harashima SI. et al. The effect of novel glucose monitoring system (flash glucose monitoring) on mental well-being and treatment satisfaction in japanese people with diabetes. Adv Ther 2018; 35: 72-80
  • 13 Scott EM, Bilous RW, Kautzky-Willer A. Accuracy, user acceptability, and safety evaluation for the freestyle libre flash glucose monitoring system when used by pregnant women with diabetes. Diabetes Technol Ther 2018; 20: 180-188
  • 14 Müller N, Kloos C, Sämann A. et al. Evaluation of a treatment and teaching refresher programme for the optimization of intensified insulin therapy in type 1 diabetes. Patient Educ Couns 2013; 93: 108-113
  • 15 Müller UA, Hunger-Dathe W, Müller N. et al. Metabolic control and hypoglycaemia 1 year after participation in the structured teaching and treatment programme “insulin pump therapy for adult patients with diabetes mellitus type 1 (subito)”. Diabetologie 2007; 2: 161-168
  • 16 Kuniss N, Müller UA, Kloos C. et al. Diabetes-related distress is reduced in people with type 1 but not type 2 diabetes after participation in a diabetes treatment and teaching programme. Diabetes Metab 2017; pii S1262-pii S3636 (17)30582-7 DOI: 10.1016/j.diabet.2017.11.008.
  • 17 Kuniss N, Müller UA, Kloos C. et al. Reduction of HbA1c and diabetes-related distress after intervention in a diabetes day care clinic in people with type 2 diabetes but not with type 1 diabetes. Exp Clin Endocrinol Diabetes 2018; 126: 242-248
  • 18 Reddy M, Jugnee N, El Laboudi A. et al. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med 2018; 35: 483-490
  • 19 Herman A, Aerts O, Baeck M. et al. Allergic contact dermatitis caused by isobornyl acrylate in Freestyle® Libre, a newly introduced glucose sensor. Contact Dermatitis 2017; 77: 367-373
  • 20 Charleer S, Mathieu C, Nobels F. et al. Accuracy and precision of flash glucose monitoring sensors inserted into the abdomen and upper thigh compared with the upper arm. Diabetes Obes Metab 2018; 20: 1503-1507
  • 21 Kramer G, Kuniss N, Jörgens V. et al. Prospective analysis of principles and frequency of self-adjustment of insulin dose in people with diabetes type 1 before and after participation in a diabetes treatment and teaching programme. Diabetes Res Clin Pract 2016; 119: 65-70
  • 22 Sämann A, Mühlhauser I, Bender R. et al. Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 2005; 48: 1965-1970